GlaxoSmithKline said the European Medicines Agency has accepted a marketing authorisation application (MAA) for its daprodustat treatment of chronic kidney disease (CKD).
The MAA includes positive data from the ASCEND Phase III clinical trial programme, which included five pivotal studies assessing the efficacy and safety of daprodustat for the treatment of anaemia across the course of CKD.
